RxDoctor Payments Data

Marilyn Jerome

Gynecology · Washington, DCNPI 1558415414

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $11,400 of the $13,578 with a category attached, or 84.0%. Astellas Pharma US Inc accounts for 88.2% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2023 at $6,829 and has fallen 85.4% since, to $1,000 in 2025.

$13,578in general payments, 2019–2025

Across 88 payments — averaging $154.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$12K
  • AbbVie$240
  • Pfizer$222
  • Renovia Inc$161
  • Myriad Women's Health, Inc.$156
  • Astellas Pharma Global Development$118
  • plus $701 from 23 others

What the payments were for

  • Speaking & faculty fees$11,40084%
  • Travel & lodging$1331%
  • Food & beverage$2,02815%
  • Education$160%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few gynecology providers in District of Columbiato place this figure against a meaningful peer group, so we don't.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProliaDenosumab13$22,628
Estradiol138$15,670
PremarinEstrogens, Conjugated29$13,507
YuvafemEstradiol43$9,259
EstringEstradiol18$9,193
Estradiol (Twice Weekly)Estradiol32$4,091
ProgesteroneProgesterone, Micronized45$1,976
Raloxifene Hcl24$1,713
Estradiol (Once Weekly)Estradiol16$1,229
Alendronate Sodium69$1,063
ValacyclovirValacyclovir Hcl19$800

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin, Estring$222$22,70047 claims
AmgenProlia$34$22,62813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few gynecology providers in District of Columbiaon file to place this against a meaningful peer group, so we don't.

Other gynecology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →